Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada

TOKYO--(BUSINESS WIRE)--Aug 9, 2023--

Related Keywords

United States ,Canada ,Tokyo ,Japan ,Meiji ,Hokkaido ,Seika Pharma ,Daikichiro Kobayashi ,Yasushi Miyazawa ,Meiji Seika Pharma Co Ltd ,Meiji Pharma United States Inc ,Representative Director ,Psoriasis Area Severity Index ,Meiji Seika ,Meiji Pharma United States ,Business Wire ,Nation World ,Region ,